Chronic graft-versus-host disease (cGVHD) is one of the major causes of late mortality after allogenic hematopoietic stem cell transplantation. Moderate-to-severe cGVHD is associated …

2024年8月16日 · Purpose: Sclerotic chronic graft-versus-host disease (cGVHD) represents a highly morbid and refractory form of cGVHD, and novel therapies for sclerotic cGVHD are …

2024年5月2日 · Primary endpoint was treatment success (TS) at 6 months defined as patient being alive, achieving PR or CR of cGVHD, having no relapse of underlying disease and …

2019年3月14日 · Since that publication, 2 major advances have occurred: first, outcome studies have shown that <20% of patients with cGVHD achieve a durable partial (PR) or complete …

6 天之前 · Eighty-two percent of patients had severe cGVHD with a median of three organs involved. ... including 14.7% complete remission (CR) and 42.6% partial response (PR). The …

For cGVHD, a partial response (PR) was defined as a change from extensive to limited stage or a higher than 50% improvement in objective parameters of cGVHD manifestations, such as …

北京大学人民医院应用小剂量MTX方案作为cGVHD的一线治疗和难治性cGVHD的挽救治疗，用量5~10 mg/m 2 第1、3（或4）、8天给药，此后每周1次，直至GVHD症状缓解或不良反应不能耐 …

2024年7月31日 · Chronic graft-versus-host disease (cGVHD) is a serious complication of allogeneic hematopoietic cell transplant. The development of cGVHD involves a complex,...

2024年12月1日 · Steroid-refractory acute and chronic graft-versus-host disease (SR-a/cGvHD) represents a potential life-threatening complication following allogeneic stem-cell …

2024年1月1日 · Most GvHD trials are focused on the ORR and partial response rates (PRR). The evidence for optimal agents for each organ is limited, and therefore, our study results are …